New Age Alpha Advisors LLC Invests $507,000 in Ascendis Pharma A/S (NASDAQ:ASND)

New Age Alpha Advisors LLC bought a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 3,680 shares of the biotechnology company’s stock, valued at approximately $507,000.

Several other institutional investors have also bought and sold shares of the stock. Groupama Asset Managment bought a new position in shares of Ascendis Pharma A/S during the third quarter valued at $60,000. Janus Henderson Group PLC lifted its holdings in Ascendis Pharma A/S by 6.8% during the 3rd quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock valued at $625,075,000 after purchasing an additional 267,881 shares during the last quarter. Frazier Life Sciences Management L.P. acquired a new position in Ascendis Pharma A/S in the third quarter valued at about $19,908,000. Zimmer Partners LP bought a new stake in Ascendis Pharma A/S during the third quarter worth about $11,646,000. Finally, American Century Companies Inc. increased its holdings in shares of Ascendis Pharma A/S by 17.5% during the fourth quarter. American Century Companies Inc. now owns 407,294 shares of the biotechnology company’s stock worth $56,072,000 after buying an additional 60,548 shares in the last quarter.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ ASND opened at $151.43 on Wednesday. The firm has a 50 day moving average price of $145.13 and a 200 day moving average price of $137.86. The stock has a market cap of $9.19 billion, a P/E ratio of -21.33 and a beta of 0.61. Ascendis Pharma A/S has a 52-week low of $111.09 and a 52-week high of $169.37.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.64. Analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on ASND shares. JPMorgan Chase & Co. boosted their price objective on Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 18th. The Goldman Sachs Group upped their price target on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Morgan Stanley set a $180.00 price objective on shares of Ascendis Pharma A/S in a research report on Tuesday, February 18th. UBS Group assumed coverage on shares of Ascendis Pharma A/S in a research report on Tuesday, January 7th. They set a “buy” rating and a $196.00 target price on the stock. Finally, Evercore ISI raised their price target on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an “outperform” rating in a report on Tuesday, February 18th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $204.64.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.